Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone Hemisuccinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | PGR | P06401 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | F2 | P00734 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 2/20 | 0.56 |
| ▸ | IL6 | P05231 | 1/20 | 0.56 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone Hemisuccinate SCHEMBL40947 | 0.90 | NR3C1 (0.85) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Methylprednisolone Hemisuccinate SCHEMBL10953512 | 0.90 | NR3C1 (0.85) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Methylprednisolone Hemisuccinate SCHEMBL1169509 | 0.90 | NR3C1 (0.85) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone Hemisuccinate SCHEMBL122046 | 0.89 | HIF1A (1.00) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone Hemisuccinate SCHEMBL871872 | 0.89 | HIF1A (1.00) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Methylprednisolone Hemisuccinate SCHEMBL18321784 | 0.88 | NR3C1 (0.81) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Methylprednisolone Phosphoric Acid SCHEMBL1237362 | 0.87 | PGR (0.78) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Methylprednisolone Hemisuccinate SCHEMBL8968978 | 0.86 | CYP3A4 (0.64) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Methylprednisolone Hemisuccinate SCHEMBL1030222 | 0.86 | NR3C1 (0.79) | HIF1ALMNANR3C1PGRCYP3A4 | |
| Prednisolone Hemisuccinate SCHEMBL3710487 | 0.86 | HIF1A (0.94) | HIF1ALMNANR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042561-B2 | Hydrophobic molecule-induced branched polymer aggregates and their use | ANP TECHNOLOGIES, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240016754-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TAXANE NANOAGGREGATES AND USE THEREOF | FULGENT GENETICS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023177629-A1 | POLYMER NANOAGGREGATE PHARMACEUTICAL COMPOSITION AND USE THEREOF | ANP TECHNOLOGIES, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178038-A1 | NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF | FULGENT GENETICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
| EP-3925625-A1 | HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE | ANP Technologies, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021046497-A2 | ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF | SHEN HAIFA (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-2661281-B1 | HYDROPHOBIC MOLECULE-INDUCED BRANCHED POLYMER AGGREGATES AND THEIR USE | ANP TECH INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210059939-A1 | Hydrophobic Molecule-Induced Branched Polymer Aggregates and their Use | FULGENT GENETICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200392289-A1 | Biodegradable Polymer and Use Thereof | FULGENT GENETICS, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-1999040787-A1 | MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040907-A1 | METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS | MEDINOX, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5916910-A | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore | MEDINOX, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| US-5916596-A | WATER INSOLUBLE DRUGS AND DRUG DELIVERY | VIVORX PHARMACEUTICALS, INC. (US) | 1999-06-29 | — | — | US | disclosed |
| WO-1999000113-A9 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS INC (US) | 1999-04-08 | — | — | WO | disclosed |
| US-5875776-A | Dry powder inhaler | VIVORX PHARMACEUTICALS, INC. (US) | 1999-03-02 | — | — | US | disclosed |
| WO-1999000113-A1 | NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998055453-A1 | CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| WO-1998014174-A1 | PROTEIN STABILIZED PHARMACOLOGICALLY ACTIVE AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF | VIVORX PHARMACEUTICALS, INC. (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997037708-A1 | DRY POWDER INHALER | VIVORX PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392289-A1 | Biodegradable Polymer and Use Thereof | PBK, PUF60, CD47 | NR3C1 4217/4885HIF1A 2315/4885LMNA 692/4885 |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | NR3C1 1611/4885HIF1A 721/4885LMNA 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.